Patient and procedural information
rheumatoid arthritis, autoimmune disorders, Paget’s Disease, spondylolisthesis, spondylosis, stenosis
RHEUMATOID ARTHRITIS, DEGENERATIVE DISC DISEASE, AUTOIMMUNE DISORDERS, SPONDYLOLISTHESIS, HERNIATED DISC, SPONDYLOSIS, STENOSIS
A total of 104 patients were enrolled in the study from four centers. Nine (9) patients were excluded from statistical analysis for either lack of follow-up (n = 6), or patient self-withdrew from study (n = 3). Thus, 95 patients (48 cervical; 47 lumbar) were included in our data analysis because they met the inclusion criteria and had at least one follow-up (6- and/or 12-month). There were 48 (50.5%) male and 47 (49.5%) female patients with a mean age of 56.2 ± 9.4 years (range 32–78). Patient demographics and clinical characteristics are described in Table Patient demographics and clinical characteristicsThere were no instances reported of Paget’s Disease (0.0%), or autoimmune disorders excluding rheumatoid arthritis (0.0%)The most frequent diagnoses and indications for spinal fusion surgery were spinal stenosis (69.5%), Degenerative Disc Disease DDD (63.2%), spondylosis (51.6%), spondylolisthesis (26.3%), and herniated disc (14.7%) (Table Procedural detailsThe study protocol allowed up to 30% of other graft material to be used in addition to ViBone, per physician choice based on the patient’s clinical needs. Other graft materials used by study investigators were autologous local bone, platelet rich plasma, blood, bone marrow, cancellous bone chips, demineralized bone matrix (DBM), and other (non-DBM) allograft materials. No patients receiving ViBone required harvesting of ICBG.